Jazz Pharma officer plans sale of 1,200 shares

Jazz Pharmaceuticals plc (JAZZ) received a notice that officer Neena Patil plans to sell 1,200 shares of common stock under Rule 144.

Available on EDGAR 09/10/2026 - 04:06 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) received a notice that officer Neena Patil plans to sell 1,200 shares of common stock under Rule 144. The shares were acquired as restricted stock from the issuer on March 5, 2026 and are proposed to be sold on September 10, 2026 on NASDAQ.

The filing lists an aggregate market value of $289,128 for the planned sale through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Figures

Shares proposed to be sold: 1,200 shares Aggregate market value: $289,128 Acquisition date of restricted stock: March 5, 2026 +1 more

4 metrics

Shares proposed to be sold 1,200 shares Common stock under Rule 144 notice for Neena Patil

Aggregate market value $289,128 Reported for the 1,200 Jazz Pharmaceuticals shares proposed to be sold

Acquisition date of restricted stock March 5, 2026 Date the 1,200 restricted shares were acquired from the issuer

Proposed sale date September 10, 2026 Proposed sale date of the 1,200 Jazz Pharmaceuticals shares on NASDAQ

Key Terms

Rule 144, Restricted Stock, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock financial

"Common | 03/05/2026 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

aggregate market value financial

"Common ... | 1200 | 289128.00 | ... | 09/10/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jazz Pharmaceuticals (JAZZ) disclose in this Form 144 filing?

The filing states that officer Neena Patil intends to sell 1,200 shares of Jazz Pharmaceuticals common stock under Rule 144, with an aggregate market value of $289,128, through Morgan Stanley Smith Barney LLC Executive Financial Services.

How many JAZZ shares are proposed to be sold and at what value?

The notice covers a proposed sale of 1,200 shares of Jazz Pharmaceuticals common stock, with an aggregate market value of $289,128 as reported in the Form 144.

When were the JAZZ shares acquired and when are they proposed to be sold?

The 1,200 shares were acquired as restricted stock from Jazz Pharmaceuticals on March 5, 2026 and are proposed to be sold on September 10, 2026 on NASDAQ.

What type of security is covered by this Jazz Pharmaceuticals (JAZZ) Form 144?

The Form 144 relates to common stock of Jazz Pharmaceuticals, held as restricted stock that was acquired from the issuer and is now proposed for resale pursuant to Rule 144.

Which broker is named for the planned JAZZ share sale?

The planned sale of Jazz Pharmaceuticals common stock is listed as being through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001783908
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
SEC File Number	001-33500
Address of Issuer	Fifth Floor, Waterloo Exchange Waterloo Road Dublin 4 IRELAND D04 E5W7
Phone	011-353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	NEENA PATIL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1200	289128.00	64914577	09/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/05/2026	Restricted Stock	Issuer			1200	03/05/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Neena M Patil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)